Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | KIF5B | P33176 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13791461 | 0.83 | KDR (0.47) | KDRRETKIF5BLCKPDGFRA | |
| SCHEMBL298522 | 0.82 | PDGFRB (0.54) | KDRRETKIF5BLCKPDGFRA | |
| SCHEMBL4374263 | 0.80 | KDR (0.53) | KDRRETKIF5BLCKPDGFRA | |
| SCHEMBL4383506 | 0.78 | FLT4 (0.58) | KDRRETLCKPDGFRAEGFR | |
| SCHEMBL4384409 | 0.77 | ABCB11 (0.58) | KDRRETLCKPDGFRAEGFR | |
| SCHEMBL1401696 | 0.77 | FLT4 (0.48) | KDRRETLCKPDGFRAEGFR | |
| SCHEMBL13471995 | 0.77 | KDR (0.59) | KDRRETKIF5BLCKPDGFRA | |
| SCHEMBL13791487 | 0.77 | KDR (0.59) | KDRRETKIF5BLCKPDGFRA | |
| SCHEMBL1401740 | 0.77 | FLT4 (0.51) | KDRRETKIF5BLCKPDGFRA | |
| SCHEMBL14421786 | 0.77 | FLT4 (0.51) | KDRRETKIF5BLCKPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1474420-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-03-14 | — | — | EP | disclosed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090156821-A1 | Quinazoline compounds | ASTRAZENECA AB | 2009-06-18 | — | — | US | disclosed |
| US-20090156821-A1 | Quinazoline compounds | ASTRAZENECA AB | 2009-06-18 | — | — | US | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
| EP-1474420-A1 | QUINAZOLINE COMPOUNDS | Astrazeneca AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | VEGFA, FLT4, FLT1 | KDR 4/4885RET 3578/4885KIF5B 1459/4885 |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KDR 1084/4885RET 492/4885KIF5B 1675/4885 |
| US-20090156821-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | KDR 5/4885RET 2725/4885KIF5B 1288/4885 |
| US-20080027069-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | KDR 5/4885RET 2725/4885KIF5B 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.